Nature

Pharmacoeconomics articles from across Nature Portfolio

Pharmacoeconomics is the scientific discipline concerned with the cost and value of drugs, often with the goal of optimizing the allocation of healthcare resources. For example, pharmacoeconomic studies may compare the costs of various drugs with the outcomes, such as benefits to patients receiving the drugs and costs saved by healthcare systems owing to effective treatment or prevention of a disease.

Latest Research and Reviews

Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings
- Po-Hung Hsieh
- Alec J. Kacew
- Mark J. Ratain
ResearchOpen Access14 Mar 2022 npj Breast Cancer
Volume: 8, P: 32
The high price of anticancer drugs: origins, implications, barriers, solutions

The costs of both newly approved, and established anticancer drugs have risen dramatically in the past decade, to the point where the costs of such treatments are becoming unsustainable. In this perspective, the authors outline the extent of this problem, and how it is likely to continue, while also suggesting measures that could be taken in future to address these rising costs.
- Vinay Prasad
- Kevin De Jesús
- Sham Mailankody
Reviews14 Mar 2017 Nature Reviews Clinical Oncology
Volume: 14, P: 381-390
An extract from Taxodium distichum targets hemagglutinin- and neuraminidase-related activities of influenza virus in vitro
- Chung-Fan Hsieh
- Yu-Li Chen
- Jim-Tong Horng
ResearchOpen Access31 Oct 2016 Scientific Reports
Volume: 6, P: 36015
Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014
- P Savage
- S Mahmoud
ResearchOpen Access10 Feb 2015 British Journal of Cancer
Volume: 112, P: 1037-1041
Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales
- C Chamberlain
- S M Collin
- W Hollingworth
ResearchOpen Access25 Feb 2014 British Journal of Cancer
Volume: 111, P: 1693-1702
Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression
- J Winner
- J D Allen
- A Spahic-Mihajlovic
ResearchOpen Access19 Mar 2013 Translational Psychiatry
Volume: 3, P: e242

All Research & Reviews

News and Comment

Speed and oversight: FDA Commissioner Gottlieb acts on pledges
- Chris Morrison
News11 Oct 2017 Nature Biotechnology
Volume: 35, P: 898-899
Epic $12 billion deal and FDA's approval raise CAR-T to new heights
- Elie Dolgin
News11 Oct 2017 Nature Biotechnology
Volume: 35, P: 891-892
Angst about exclusivity: The potential cost of incentivizing makers of generic drugs
- Shraddha Chakradhar
- Roxanne Khamsi
News01 Oct 2017 Nature Medicine
Volume: 23, P: 1114-1116
LifeArc splashes out, fuelled by Keytruda

News01 Aug 2017 Nature Biotechnology
Volume: 35, P: 693
The curse of uncertainty

Proposed US budget cuts and the impending exit of the UK from the European Union have the potential to destabilize the global biomedical-research enterprise. In the meantime, the uncertainty of not knowing just how bad the effects will be will inflict its own damage.

Editorial05 May 2017 Nature Medicine
Volume: 23, P: 527
Billion-dollar deals end eras of Ariad and Actelion
- Melanie Senior
News07 Mar 2017 Nature Biotechnology
Volume: 35, P: 183-184

All News & Comment

Search

Advanced search

Quick links